Please assess the completion status of the following clinical trial:

Trial Title: Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Dose escalation cohorts: Patients with histologically or cytologically confirmed diagnosis of malignancy (including lymphoma) with demonstrated progression of a tumor for whom there is no available therapy likely to convey clinical benefit AND who have not been previously treated with a PD-1/PD-L1 inhibitor. These patients do not require measurable disease~* Dose expansion cohorts: Patients with histologically or cytologically confirmed diagnosis of 1 of specified tumors with measurable disease per RECIST 1.1 or Lugano criteria. Some patients may have been previously treated with a PD-1 or PD-L1 inhibitor~* Eastern Cooperative Oncology Group performance status of 0 or 1~* Adequate organ and bone marrow function~Key Exclusion Criteria:~* Prior treatment with any LAG-3 targeting biologic or small molecule~* Radiation therapy within 2 weeks prior to randomization and not recovered to baseline from any AE due to radiation~* Untreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune disease~* Corticosteroid therapy (\>10 mg prednisone/day or equivalent) within 1 week prior to the first dose of study drug~* Myocardial infarction within 6 months~Note: Other protocol defined Inclusion / Exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monotherapy (REGN3767) (Type: EXPERIMENTAL): Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
- Combination Therapy (REGN3767+cemiplimab) (Type: EXPERIMENTAL): Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion

Based on this trial design, predict the completion outcome and termination type (if applicable).